Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review

Overview of attention for article published in Hereditary Cancer in Clinical Practice, January 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

policy: 1 policy source

twitter: 1 X user

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 26 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

pembrolizumab

Cited by Canadian Agency for Drugs and Technologies in Health on 22 Sep 2021

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.